Leap Therapeutics reports updated results from Phase B of DeFianCe study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Study Results: Leap Therapeutics reported updated results from the DeFianCe study, showing significant improvements in progression-free survival (PFS) for patients with advanced microsatellite stable colorectal cancer treated with sirexatamab, DKN-01, in combination with bevacizumab and chemotherapy.
Patient Subgroups: The data highlighted particularly strong benefits for patients with high levels of DKK1, those who were VEGF-naive, and individuals with liver metastasis, indicating a positive trend in overall response rate (ORR) and PFS across the second-line CRC population.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
